drugset / Trial / NCT06879782

Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease

NCT06879782

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.

Timeline

Start
2024-03-28
Primary completion
2026-03-28
Completion
2026-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Lifitegrast Unknown Other

Indications